How to effectively kill cancer cells? You can try Larotrectinib!
Cancer cells are special cells that have gone out of control due to genetic mutations and cause tumor formation. Cell division is a normal process the body uses for growth and repair. Typically, a mother cell divides to form two daughter cells that can be used to build new body tissue or to replace cells that have died due to aging and damage. Cell division ends when more daughter cells are no longer needed. Cancer cells, however, replicate themselves indefinitely, increase forever, and may spread from one part of the body to another or even to multiple parts of the body through distant metastasis, continuing to eat away at other body tissues and leading to cancer.
Cancer cells are hazardous and unique compared to normal cells. Usually, cells cannot replicate themselves indefinitely due to the depletion of telomerase. But cancer cells have a unique ability to be “immortal.” They bypass the limits of cell division and can actively repair telomerase for uninterrupted life extension. While the telomeres of most cells shorten after each division, eventually leading to cell death, cancer cells can accumulate indefinitely over time, which is the leading cause of tumors. Cancer cells can be broadly classified into BenchChem and malignant, with the former usually not spreading to other tissues. At the same time, the latter has more apparent characteristics of infiltrating tissues and easily metastasizing, thus highly susceptible to developing malignant tumors or cancer.
In the fight against cancer, medical doctors have worked tirelessly to discover many new drugs to treat cancer, and now we would like to introduce a new drug, Larotrectinib.
What is Larotrectinib?
Larotrectinib, also known as ARRY-470 and LOXO-101, is an oral, potent, ATP-competitive inhibitor of TRKA, TRKB, and TRKC, all members of the receptor tyrosine kinase family of neurotrophin receptors.
The NTRK gene encodes a TRK protein. Chromosomal rearrangements involving NTRK gene fusions may result in activated chimeric TRK fusion proteins that act as oncogenic drivers and promote cell proliferation and survival in tumor cell lines.
Larotrectinib was initially granted orphan drug status in 2015 for soft tissue sarcoma and received breakthrough therapy designation in 2016 for treating NTRK-fused metastatic solid tumors. Several clinical trial results were published in 2017. on November 26, 2018, Larotrectinib received FDA approval.
Larotrectinib was the first drug specifically developed and approved for the treatment of any cancer containing specific mutations. Several earlier drugs, including pembrolizumab, were eventually approved by the FDA to treat specific mutations independent of cancer type. Still, these drugs were initially developed for specific cancer types. The U.S. Food and Drug Administration (FDA) considers it a Class I drug.
Also check : CCNP Certification: The Key to Unlocking Expert-Level Networking Skills